RU2016140455A - Способ получения композиции иммуноглобулинов - Google Patents
Способ получения композиции иммуноглобулинов Download PDFInfo
- Publication number
- RU2016140455A RU2016140455A RU2016140455A RU2016140455A RU2016140455A RU 2016140455 A RU2016140455 A RU 2016140455A RU 2016140455 A RU2016140455 A RU 2016140455A RU 2016140455 A RU2016140455 A RU 2016140455A RU 2016140455 A RU2016140455 A RU 2016140455A
- Authority
- RU
- Russia
- Prior art keywords
- antibody preparation
- preparation
- antibody
- igm
- immunoglobulins
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims 7
- 102000018358 immunoglobulin Human genes 0.000 title claims 7
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 229940072221 immunoglobulins Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000380 propiolactone Drugs 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 230000003171 anti-complementary effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 244000309711 non-enveloped viruses Species 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (25)
1. Препарат антитела, содержащий иммуноглобулины, где по меньшей мере 15% от всех иммуноглобулинов представляют собой IgM, и где препарат обладает вирусной безопасностью по отношению к оболочечным и безоболочечным вирусам, имеет антикомплементарную активность ≤1 CH50/мг белка и является стабильным в жидкой форме в течение по меньшей мере 6 месяцев при хранении при 2-8оC.
2. Препарат антитела по п.1, где иммуноглобулины являются химически немодифицированными.
3. Препарат антитела по п.1, где препарат не обрабатывают во время его процесса получения β-пропиолактоном.
4. Препарат антитела по п. 1, где иммуноглобулины являются ферментативно немодифицированными.
5. Препарат антитела по п. 4, где препарат не обрабатывают добавленной протеазой.
6. Препарат антитела по п. 4, где препарат не обрабатывают добавленной протеазой.
7. Препарат антитела по п. 1, дополнительно содержащий IgG и IgA.
8. Препарат антитела по п. 1, где препарат содержит по меньшей 20% IgM.
9. Препарат антитела по п. 1, который является стабильным в течение по меньшей мере 2 лет при хранении при 2-8оС.
10. Препарат антитела по п. 1, где препарат содержит от 20% до 30% IgM.
11. Препарат антитела по п. 1, дополнительно содержащий стабилизирующее средство.
12. Препарат антитела по п. 11, где стабилизирующее средство содержит глицин.
13. Препарат антитела, содержащий IgM, имеющий протеолитическую активность менее чем 8 ед/л, где препарат содержит по меньшей мере 20% IgM.
14. Препарат антитела по п.13, где иммуноглобулины являются химически немодифицированными.
15. Препарат антитела по п.14, где препарат не обрабатывают во время его процесса получения β-пропиолактоном.
16. Препарат антитела по п. 13, где иммуноглобулины являются ферментативно немодифицированными.
17. Препарат антитела по п. 13, дополнительно содержащий IgG и IgA.
18. Препарат антитела по п. 13, где препарат содержит от 20% до 30% IgM.
19. Препарат антитела по любому из предшествующих пунктов, где препарат пригоден для внутривенного введения человеку.
20. Препарат антитела по любому из пп. 1-19 для применения в медицине.
21. Препарат антитела по п. 20 для применения в лечении иммунологического нарушения или бактериальной инфекции.
22. Препарат антитела по п.21, где иммунологическое нарушение представляет собой нарушение с дефицитом IgM.
23. Применение препарата антитела по любому из пп. 1-19 для изготовления лекарственного средства для лечения иммунологического нарушения или бактериальной инфекции.
24. Способ лечения пациента, включающий введение препарата антитела по любому из пп.1-19.
25. Способ лечения по п.24, где пациент страдает иммунологическим нарушением или бактериальной инфекцией.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1006753.6 | 2010-04-22 | ||
| GBGB1006753.6A GB201006753D0 (en) | 2010-04-22 | 2010-04-22 | Process for preparing an immunolobulin composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149743A Division RU2612899C2 (ru) | 2010-04-22 | 2011-04-21 | Способ получения композиции иммуноглобулинов |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016140455A true RU2016140455A (ru) | 2018-12-17 |
| RU2016140455A3 RU2016140455A3 (ru) | 2020-04-02 |
| RU2765738C2 RU2765738C2 (ru) | 2022-02-02 |
Family
ID=42270688
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149741A RU2617532C2 (ru) | 2010-04-22 | 2011-04-21 | Препараты антител |
| RU2017111820A RU2749732C2 (ru) | 2010-04-22 | 2011-04-21 | Препараты антител |
| RU2016140455A RU2765738C2 (ru) | 2010-04-22 | 2011-04-21 | Способ получения композиции иммуноглобулинов |
| RU2012149743A RU2612899C2 (ru) | 2010-04-22 | 2011-04-21 | Способ получения композиции иммуноглобулинов |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149741A RU2617532C2 (ru) | 2010-04-22 | 2011-04-21 | Препараты антител |
| RU2017111820A RU2749732C2 (ru) | 2010-04-22 | 2011-04-21 | Препараты антител |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149743A RU2612899C2 (ru) | 2010-04-22 | 2011-04-21 | Способ получения композиции иммуноглобулинов |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US8900806B2 (ru) |
| EP (2) | EP2560682B2 (ru) |
| JP (4) | JP6283517B2 (ru) |
| KR (2) | KR101872747B1 (ru) |
| CN (3) | CN107080842A (ru) |
| AU (2) | AU2011244240B2 (ru) |
| CA (2) | CA2796409A1 (ru) |
| CO (2) | CO6640238A2 (ru) |
| ES (2) | ES2551605T5 (ru) |
| GB (1) | GB201006753D0 (ru) |
| HU (2) | HUE025853T2 (ru) |
| IL (2) | IL222373A (ru) |
| MX (2) | MX337060B (ru) |
| PL (2) | PL2560691T3 (ru) |
| RU (4) | RU2617532C2 (ru) |
| SG (2) | SG184844A1 (ru) |
| WO (2) | WO2011131786A2 (ru) |
| ZA (2) | ZA201208540B (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| FR2959821B1 (fr) * | 2010-05-05 | 2012-07-06 | Lab Francais Du Fractionnement | Procede de mesure de l'activation du complement par des igg |
| FR2974301B1 (fr) | 2011-04-20 | 2013-08-23 | Lab Francais Du Fractionnement | Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes |
| FR2977893B1 (fr) * | 2011-07-11 | 2015-02-20 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre d'immunoglobulines polyvalentes |
| EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
| EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
| MX360245B (es) * | 2012-03-09 | 2018-10-26 | Csl Behring Ag | Composiciones que comprenden inmunoglobulinas de tipo secretor. |
| KR20150115639A (ko) * | 2014-04-04 | 2015-10-14 | 전숙영 | 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제 |
| WO2016011054A2 (en) * | 2014-07-15 | 2016-01-21 | The Regents Of The University Of California | Novel treatment for polycystic kidney disease |
| SI4209499T1 (sl) | 2015-08-13 | 2025-01-31 | Amgen Inc. | Globinsko nabito filtriranje proteinov, ki vežejo antigen |
| US20190076523A1 (en) | 2016-03-14 | 2019-03-14 | Biotest Ag | Treatment of severe community acquired pneumonia |
| EP3275897A1 (en) * | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
| RU2660584C1 (ru) * | 2017-06-06 | 2018-07-06 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ определения FC-функции препаратов иммуноглобулина человека |
| CA3081801C (en) * | 2017-11-29 | 2022-12-20 | F. Hoffman-La Roche Ag | Target interference suppressed anti-drug antibody assay |
| EP3747903A1 (en) | 2019-06-07 | 2020-12-09 | Biotest AG | Method and kit for testing potency of immunoglobulin compositions |
| JP2023521178A (ja) * | 2020-04-10 | 2023-05-23 | バヌディス ゲーエムベーハー | 予防および治療における自然抗体 |
| CN115697408A (zh) * | 2020-06-03 | 2023-02-03 | 基立福环球运营有限公司 | 超免疫igg和/或igm组合物及其制备方法及自捐献者获得超免疫人血浆的方法 |
| JP2023532473A (ja) * | 2020-07-10 | 2023-07-28 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | ヒト血漿由来免疫グロブリンｍを含む組成物を得るための方法 |
| CN111944043B (zh) * | 2020-09-01 | 2023-05-09 | 华兰生物工程重庆有限公司 | 一种从血浆废弃物中提取IgM的方法 |
| EP4193155A1 (en) | 2020-11-19 | 2023-06-14 | Biotest AG | Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19 |
| CA3223881A1 (en) | 2021-07-29 | 2023-02-02 | Roopsee ANAND | Method of purifying immunoglobulin g and uses thereof |
| WO2024200757A1 (en) | 2023-03-29 | 2024-10-03 | Csl Behring Ag | Methods of identifying immunoglobulin associated with adverse reactions |
| WO2025008781A1 (en) | 2023-07-04 | 2025-01-09 | Csl Behring Ag | Method of purification |
| WO2025229607A1 (en) | 2024-05-03 | 2025-11-06 | Csl Behring Ag | Systems and methods for solid-liquid separation |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US136556A (en) | 1873-03-04 | Improvements in button-fastenings | ||
| DE2901822A1 (de) * | 1979-01-18 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt |
| US4371520A (en) * | 1981-10-28 | 1983-02-01 | The Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
| DE3310150A1 (de) * | 1983-03-21 | 1984-09-27 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation |
| IL90281A (en) | 1988-06-06 | 1994-10-07 | Miles Inc | Preparations containing MGI antibodies |
| DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| US4939176A (en) | 1988-12-20 | 1990-07-03 | Miles Inc. | Viral inactivation process |
| DE3927111C3 (de) † | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
| DE3927112C1 (ru) | 1989-08-17 | 1990-10-25 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| US5367054A (en) * | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| WO1997003706A1 (fr) | 1995-07-14 | 1997-02-06 | Croix-Rouge De Belgique | Procede et installation d'inactivation de contaminants presents dans des produits sanguins |
| DK0764658T3 (da) | 1995-09-22 | 2002-04-22 | Zlb Bioplasma Ag | Fremgangsmåde til fremstilling af immunoglobuliner ud fra fraktioner, som opstår ved fraktionering af blodplasma fra mennesker |
| EP0835880A1 (de) | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
| JP3987599B2 (ja) * | 1996-12-05 | 2007-10-10 | 日本製薬株式会社 | 筋ジストロフィー治療剤 |
| JPH10167894A (ja) * | 1996-12-11 | 1998-06-23 | Mitsubishi Gas Chem Co Inc | ビスマス置換希土類鉄ガーネット単結晶膜の製造法 |
| US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| AU753468B2 (en) * | 1998-06-09 | 2002-10-17 | Csl Behring Ag | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| RU2178309C2 (ru) * | 2000-01-12 | 2002-01-20 | Российский научно-исследовательский институт геронтологии | Антитимоцитарный глобулин для внутривенного введения и способ его получения |
| RU2192279C2 (ru) * | 2000-09-07 | 2002-11-10 | Нижегородское государственное предприятие по производству бактерийных препаратов | Способ получения иммуноглобулинового препарата |
| EP1337280B1 (en) | 2000-11-13 | 2013-09-04 | Bayer Intellectual Property GmbH | Method of inactivating microorganisms in a fluid using ultraviolet radiation |
| FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
| JP4191037B2 (ja) * | 2001-11-02 | 2008-12-03 | 日本テクノ株式会社 | 滅菌用振動攪拌装置並びに振動攪拌装置を用いる滅菌装置及び滅菌方法 |
| RU2255766C2 (ru) * | 2003-03-05 | 2005-07-10 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" | Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата |
| JP4939929B2 (ja) | 2003-03-26 | 2012-05-30 | ポール，サッドヒル | タンパク質分解抗体および共有結合抗体 |
| WO2005044856A2 (en) | 2003-10-27 | 2005-05-19 | Wyeth | Removal of high molecular weight aggregates using hydroxyapatite chromatography |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| EP1709077A1 (en) | 2004-01-30 | 2006-10-11 | Suomen Punainen Risti Veripalvelu | Process for the manufacture of virus safe immunoglobulin |
| DK1718675T3 (da) | 2004-02-27 | 2013-07-15 | Octapharma Ag | Fremgangsmåde til at tilvejebringe en oprenset virussikker antistoftilberedning |
| WO2006077471A2 (en) | 2004-12-10 | 2006-07-27 | Novimmune S.A. | Combining therapies targeting multiple toll-like receptors and use thereof |
| WO2006064373A2 (en) | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
| KR101157174B1 (ko) | 2005-11-24 | 2012-06-20 | 삼성전자주식회사 | 세포 또는 바이러스의 신속한 파괴 방법 및 장치 |
| DE102005062634A1 (de) | 2005-12-23 | 2007-06-28 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung |
| FR2899112B1 (fr) | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament. |
| FR2899111B1 (fr) | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. |
| US8354076B2 (en) | 2006-10-02 | 2013-01-15 | Palo Alto Research Center Incorporated | Fluid stirring mechanism |
| EP1950225A1 (de) | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| JP2011519974A (ja) | 2008-05-12 | 2011-07-14 | ストロックス バイオファーマスーティカルズ，エルエルシー | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に特異的な抗体製剤 |
| RU2457863C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
| RU2457861C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| NZ591514A (en) | 2011-03-03 | 2013-11-29 | Kode Biotech Ltd | Assay method |
-
2010
- 2010-04-22 GB GBGB1006753.6A patent/GB201006753D0/en not_active Ceased
-
2011
- 2011-04-21 KR KR1020127030527A patent/KR101872747B1/ko active Active
- 2011-04-21 WO PCT/EP2011/056486 patent/WO2011131786A2/en not_active Ceased
- 2011-04-21 ES ES11715567T patent/ES2551605T5/es active Active
- 2011-04-21 CN CN201611045494.0A patent/CN107080842A/zh active Pending
- 2011-04-21 WO PCT/EP2011/056487 patent/WO2011131787A2/en not_active Ceased
- 2011-04-21 HU HUE11715567A patent/HUE025853T2/en unknown
- 2011-04-21 JP JP2013511592A patent/JP6283517B2/ja active Active
- 2011-04-21 SG SG2012076063A patent/SG184844A1/en unknown
- 2011-04-21 CA CA2796409A patent/CA2796409A1/en not_active Abandoned
- 2011-04-21 EP EP11715567.1A patent/EP2560682B2/en active Active
- 2011-04-21 RU RU2012149741A patent/RU2617532C2/ru active
- 2011-04-21 PL PL11715928T patent/PL2560691T3/pl unknown
- 2011-04-21 RU RU2017111820A patent/RU2749732C2/ru active
- 2011-04-21 EP EP11715928.5A patent/EP2560691B1/en active Active
- 2011-04-21 RU RU2016140455A patent/RU2765738C2/ru active
- 2011-04-21 MX MX2012012262A patent/MX337060B/es active IP Right Grant
- 2011-04-21 RU RU2012149743A patent/RU2612899C2/ru active
- 2011-04-21 KR KR1020127030528A patent/KR101860459B1/ko active Active
- 2011-04-21 JP JP2013511591A patent/JP6118248B2/ja active Active
- 2011-04-21 MX MX2012012263A patent/MX338195B/es active IP Right Grant
- 2011-04-21 CA CA2796263A patent/CA2796263C/en active Active
- 2011-04-21 AU AU2011244240A patent/AU2011244240B2/en active Active
- 2011-04-21 ES ES11715928.5T patent/ES2553385T3/es active Active
- 2011-04-21 HU HUE11715928A patent/HUE028581T2/en unknown
- 2011-04-21 AU AU2011244241A patent/AU2011244241B2/en active Active
- 2011-04-21 PL PL11715567.1T patent/PL2560682T5/pl unknown
- 2011-04-21 CN CN201180029337.XA patent/CN102939107B/zh active Active
- 2011-04-21 SG SG2012076055A patent/SG184843A1/en unknown
- 2011-04-21 CN CN201180029338.4A patent/CN102939111B/zh active Active
-
2012
- 2012-10-11 IL IL222373A patent/IL222373A/en active IP Right Grant
- 2012-10-11 IL IL222374A patent/IL222374A/en active IP Right Grant
- 2012-10-19 US US13/655,686 patent/US8900806B2/en active Active
- 2012-10-19 US US13/655,649 patent/US9243056B2/en active Active
- 2012-11-13 ZA ZA2012/08540A patent/ZA201208540B/en unknown
- 2012-11-13 ZA ZA2012/08541A patent/ZA201208541B/en unknown
- 2012-11-22 CO CO12211854A patent/CO6640238A2/es not_active Application Discontinuation
- 2012-11-22 CO CO12211856A patent/CO6640239A2/es unknown
-
2014
- 2014-10-31 US US14/529,400 patent/US9518110B2/en active Active
-
2016
- 2016-06-01 JP JP2016110121A patent/JP6612182B2/ja active Active
- 2016-06-15 JP JP2016118887A patent/JP6612186B2/ja active Active
- 2016-11-10 US US15/348,121 patent/US10059759B2/en active Active
-
2018
- 2018-07-09 US US16/029,781 patent/US10954290B2/en active Active
-
2021
- 2021-02-05 US US17/168,848 patent/US11780909B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016140455A (ru) | Способ получения композиции иммуноглобулинов | |
| ES2983475T3 (es) | Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R | |
| JP2013530950A5 (ru) | ||
| TWI445714B (zh) | 產製用於皮下使用之高濃度免疫球蛋白製備物之方法 | |
| ES2964640T3 (es) | Filtración en profundidad cargada de proteínas de unión al antígeno | |
| EA032336B1 (ru) | Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции | |
| TW201424748A (zh) | 高濃度抗體及蛋白質調配物 | |
| JP2016514132A5 (ru) | ||
| JP2013534540A (ja) | 濃縮ヒト免疫グロブリン組成物 | |
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| WO2005072772A1 (en) | Pharmaceutical compositions | |
| EA201101036A1 (ru) | Применение хлорида аммония в терапии | |
| JP5689425B2 (ja) | 血液から免疫グロブリンを得るためのシステムおよび方法 | |
| RU2018135290A (ru) | Лечение тяжелой внебольничной пневмонии | |
| JP2019508458A5 (ru) | ||
| JPWO2020128049A5 (ru) | ||
| RU2470664C2 (ru) | Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом | |
| Anitha | Covaxin vs covishield be a superhero to make India covid-free | |
| US20230277651A1 (en) | Immunoglobulin mediated vaccinations against viral diseases | |
| RU2381037C1 (ru) | Сывороточный иммунобиологический препарат для экстренной профилактики и лечения сибирской язвы | |
| Kemter | Terminal Radiation Sterilization of Combination Products | |
| BR102022006831A2 (pt) | Produção de anticorpos anti-sars-cov-2 e sua aplicação como imunobiológico para tratamento e prevenção de covid-19 | |
| RU2017126043A (ru) | Композиция от бешенства, содержащая адъювант pika | |
| Sánchez et al. | Development and pre-clinical characterization of two therapeutic equine formulations | |
| León Montero et al. | Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |